FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Promising Ziihera Data in Gastric Cancer Trial

[ Price : $8.95]

Zymeworks reports that its HER2-targeted bispecific antibody Ziihera (zanidatamab-hrii) significantly improved outcomes for patien...

Aseptic Breakdowns at Sanofis Fill-Finish Plant: FDA

[ Price : $8.95]

FDA posts a Form 483 that cites significant lapses in aseptic manufacturing practices at Sanofis sterile drug-product facility in ...

Guide on PH Waivers for Certain Generics

[ Price : $8.95]

FDA posts a final guidance entitled Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Pare...

BMS, J&J Halt Phase 3 Librexia Trial After Futility Review

[ Price : $8.95]

Bristol Myers Squibb (BMS) and Johnson & Johnson stop their Phase 3 Librexia ACS trial of the investigational anticoagulant milvex...

FDA Previews Reforms as Pazdur Takes Over CDER

[ Price : $8.95]

FDA commissioner Marty Makary and CBER director Vinay Prasad preview upcoming agency reforms during an FDA Direct podcast focused ...

Rising Concerns Over FDA Consistency, Transparency: Axios

[ Price : $8.95]

An Axios report examines growing criticism of recent FDA actions that are fueling uncertainty among drug developers and weakening ...

ACLU Sues FDA for Records on Mifepristone Review

[ Price : $8.95]

The ACLU files a lawsuit seeking to force FDA to release documents related to its ongoing safety review of mifepristone.

FDA Approves New Safety Warning for Elevidys

[ Price : $8.95]

FDA says it is approving new labeling submitted by Sarepta Therapeutics for its gene therapy Elevidys (delandistrogene moxeparvove...

Parabilis FOG-001 Wins FDA Fast Track for Desmoid Tumors

[ Price : $8.95]

FDA grants Parabilis Medicines a fast track designation for FOG-001, a first-in-class inhibitor targeting the β-catenin:TCF i...

Gileads Single-Tablet HIV Regimen Meets Trial Endpoint

[ Price : $8.95]

Gilead Sciences says its investigational single-tablet regimen combining bictegravir and lenacapavir met its primary endpoint in a...